AEAnna V. Eremeeva

Anna V. Eremeeva

*This is an algorithmically generated author record based on publicly available information.

Anna V. Eremeeva has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of Netakimab in Children and Adolescents with Moderate-to-Severe Plaque Psoriasis: Results of the Core Treatment Period (12 Weeks) of the Randomized Placebo-Controlled Phase III Clinical Trial BCD-085-16/PLANETA-KIDS

    by Nikolay N. Murashkin, Andrey L. Bakulev, Pavel V. Gorodnichev, Denis V. Zaslavskiy, Oleg R. Ziganshin, Muza M. Kokhan, Sergey V. Koshkin, Anna A. Maksimova, Yulia S. Kovaleva, Tatiana E. Pak, et al.

    Netakimab is a humanized anti-interleukin-17A monoclonal antibody, it has marketing approval for treatment of adult patients with moderate-tosevere plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. This paper provides the results of the first 12-week period of phase III BCD-085-16/PLANETA-KIDS clinical study. Objective. The aim of the BCD-085-16/PLANETA-KIDS is to evaluate netakimab efficacy and safety in pediatric patients 6+ years old with moderate-to-severe plaque psoriasis. Methods. BCD-085-16/PLANETA-KIDS (NCT06640517) is a randomized, double-blind, placebo-controlled phase III clinical study with open-label active-comparator arm (adalimumab). A total of 155 male and female patients aged from 6 to 18 years with confirmed moderate-to-severe plaque psoriasis were randomized to receive netakimab (n = 83), placebo (n = 35), or adalimumab (n = 37). Netakimab dosage was weight adjusted: for patients weighing 50 kg or more netakimab dose was 120 mg (two injections of 60 mg/ml each), for patients weighing less than 50 kg netakimab dose was 60 mg (one injection of 60 mg/ml). Patients in the Netakimab group received netakimab subcutaneously once per week for the first three weeks (induction) and once every 4 weeks thereafter (maintenance). Patients in the Placebo group received placebo in blinded manner like netakimab. Adalimumab was administered in open-label way in doses recommended by the product’s SmPC. In this study co-primary efficacy endpoints were the proportion of patients achieving PASI75 and sPGA0/1 at week 12. Results. Netakimab has shown superiority over placebo for both co-primary endpoints. The proportion of patients achieving PASI75 at week 12 was 89.2% in the Netakimab group and 14.3% in the Placebo group, odds ratio (OR) 59.0, 95% CI [16.5; 211.5] (p < 0.0001). The proportion of patients achieving sPGA0/1 at week 12 was 83.1% in the Netakimab group and 8.6% in the Placebo group, OR 54.9, 95% CI [14.6; 206.5] (p < 0.0001). The subgroup analysis has shown consistent netakimab superiority over placebo for both co-primary endpoints, regardless of age, body weight and psoriasis severity. Throughout the 12-week period netakimab has shown favorable safety profile comparable to that in the Placebo group. Conclusion. The results of the 12-week period in the BCD-085-16/PLANETA-KIDS study have shown high efficacy of netakimab compared with placebo with favorable safety profile in children aged 6 years and older and adolescents with moderate-to-severe plaque psoriasis.

  • Open Access

    The impact of clinical and demographic factors on the efficacy of divozilimab in patients with systemic sclerosis: Post hoc analysis of the randomized, double-blind, placebo-controlled phase III clinical trial LIBERIUS

    by L. P. Ananyeva, A. M. Lila, I. Z. Gaydukova, D. I. Abdulganieva, M. N. Starovoytova, G. V. Lukina, A. A. Porozova, A. V. Eremeeva, P. S. Pukhtinskaia, E. L. Nasonov

    Divozilimab (DIV) is a new monoclonal antibody drug against CD20, which has demonstrated efficacy and safety in patients with systemic sclerosis (SS) in terms of reducing skin fibrosis and stabilizing lung function. The aim of the study was to assess the dynamics of skin fibrosis according to the mRSS in SSD patients treated DIV with depending on gender, disease duration and initial lung function. Material and methods . A post hoc analysis of data from a 48-week randomized placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS was conducted. 151 patients with SS were randomized into groups treated with DIV (n=76) or Placebo (n=75). DIV was administered intravenously at 250 mg on weeks 0 and 2, and then at 500 mg once every 24 weeks. The efficacy of DIV compared to placebo in terms of reducing skin fibrosis according to the mRSS was evaluated in subgroups of patients formed by gender (female/male), disease duration at the time of therapy initiation (less than 3 years, from 3 to 5 years, and more than 5 years), as well as by initial lung function (forced vital capacity (FVC) % predicted ≥80%/Results . The average change in mRSS from baseline at week 48 in men was –6.1±2.1 in the DIV and 1.6±6.2 in Placebo (LS mean difference (LSMD) –7.5 (95% CI: –11.6; –3.4); p=0.0004). In the subgroup of women, the change in mRSS was –5.1±4.1 and –2.5±4.4 in the DIV and Placebo groups respectively (LSMD=–2.5 (95% CI: –4.0; –1.0); p=0.001). In patients with a SS duration of up to 3 years, the mRSS dynamics was the most pronounced: –5.6±4.0 in DIV compared to –0.7±6.0 in placebo (LSMD=–5.2 (95% CI: –7.4; –2.9); pConclusion . DIV is a promising and effective therapeutic option for all patients with SS, regardless of gender, although a more pronounced effect on reducing skin fibrosis can be expected in men. DIV therapy is appropriate at any SS duration, but the highest efficacy in terms of skin fibrosis is observed in patients with recently developed disease. A significant and marked reduction in skin score in patients with initially normal and reduced lung function defines the possibility of DIV therapy in a broad population of SS patients. This is promising for improving the visceral lesions prognosis during DIV therapy, especially in the case of early therapy.


  • Open Access

    Divozilimab reduces the risk of exacerbations in patients with neuromyelitis optica spectrum disorders

    by A. N. Boyko, M. N. Zakharova, T. O. Simaniv, V. M. Alifirova, E. G. Arefieva, M. A. Barabanova, Z. A. Goncharova, I. V. Greshnova, N. V. Dorogov, V. A. Dudin, et al.

    Objective: the aim of the AQUARELLE trial was to evaluate the efficacy of divozilimab compared with a historical control (placebo) and to characterise its safety in patients with neuromyelitis optica spectrum disorder (NMOSD).Material and methods. The AQUARELLE clinical trial population included patients aged 18 years and older with a diagnosis of NMOSD established in accordance with the international consensus diagnostic criteria for NMOSD (2015). The primary efficacy endpoint was the mean annual rate of confirmed exacerbations (MAR) over 6 months of treatment with divozilimab compared with a historical control, which was the placebo from the N-MOmentum study.Results. A total of 105 patients received treatment with the investigational drug divozilimab. At the time of analysis, the proportion of patients without confirmed exacerbations was 94.3% (99/105); the ARR was 0.124 (95% CI 0.056–0.276). The ARR ratio for divozilimab /historical placebo was 0.172 (90% CI 0,083–0,359), indicating the superiority of divozilimab compared to historical placebo over 6 months of therapy. During divozilimab therapy, a therapy-related decrease in lymphocyte count was reported in 16 (15.2%) patients, and infusion reactions were reported in 6 (5.7%) patients. The overall incidence of therapy-related infectious events was 6 cases (5.7%).Conclusion. Within patients with NMOSD, the use of divozilimab reduces the risk of exacerbations. The good tolerability of the drug allows divozilimab to be recommended as a new therapeutic option for patients with NMOSD.


  • Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis

    by A.N. Boyko, V.M. Alifirova, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, G.N. Mishin, E.V. Parshina, I.YE. Poverennova, S.A. Sivertseva, et al.

    Objective. To assess the efficacy and safety of long-term treatment with divozilimab in patients with relapsing multiple sclerosis (MS). Material and methods. Study No. BCD-132-EXT enrolled patients with relapsing MS who had previously received divozilimab at a dose of 500 mg in a phase II and III studies. Taking into account the participation of patients in previous studies, the total treatment duration was 4 years. The efficacy assessment was carried out using parameters associated with relapses (annualized relapse rate (ARR), time to first relapse), parameters of magnetic resonance imaging of the brain, and also included evaluation of neurological deficit. Safety monitoring included evaluation of standard laboratory parameters and reporting of adverse events. Results. A total of 44 patients were enrolled in the study, of which 93.2% (41/44) patients completed 4 years of follow-up. During the BCD-132-EXT period, the proportion of relapse-free patients was 97.7%. Over the 4 years of observation, the ARR remained consistently low, with the overall ARR over 4 years of divozilimab treatment being 0.052 (95% CI 0.028; 0.097). The 6-month confirmed disability progression (CDP) during the treatment period was observed in 4.5% (n=2) of patients. Adverse reactions, most of which were mild to moderate in severity, were reported in 59.1% (n=26) of patients. The most common adverse reactions were decreased lymphocyte count, decreased white blood cell count, decreased neutrophil count, and infusion reactions. Conclusion. The obtained results indicate the maintenance of efficacy over 4 years of therapy with divozilimab. The safety profile of divozilimab was favorable and consistent with previously obtained data.


  • Open Access

    The efficacy and safety of divozilimab in patient with systemic sclerosis: 48-week results of the randomized double-blind placebo-controlled phase III clinical study LIBERIUS

    by L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, et al.

    The aim of the study is to evaluate the efficacy, safety and immunogenicity of divozilimab (DIV), anti-CD20 monoclonal antibody, in patients with systemic sclerosis (SS).Materials and methods. Patients with SS according to ACR/EULAR (American College of Rheumatology/ European Alliance of Associations for Rheumatology) 2013 criteria with modified Rodnan skin score (mRSS) ≥10 and ≲20 and forced vital capacity (FVC) ≥40% from the due took part in the study. Infusions of DIV 250 mg were administered on weeks 0 and 2, and DIV 500 mg – on week 24 with the subsequent use in open mode, starting from week 48. This publication presents data obtained for 48 weeks of trial (before the DIV infusion at week 48). Primary endpoint was the change in the mRSS from baseline to week 48. The dynamic of FVC was estimated as the secondary endpoint. The safety evaluation included the frequency and profile of adverse events and adverse reactions (ARs). Immunogenicity was assessed by detection of binding and neutralizing anti-drug antibodies on weeks 2, 24 and 48.Results. 151 patients were randomized into two groups: DIV (n=76) and Placebo (n=75). The most were female; the median duration of the disease was about 3–4 years. The initial value of the mRSS was 14 and 13 points in DIV and PBO groups, respectively. The change of mRSS from baseline to week 48 was –5.8±1.1 points in DIV group and –2.7±1.0 points in Placebo group (adjusted mean difference (AMD) with 95% confidence interval –3.1 (–4.5; –1.7); pConclusion. Divosilimab has demonstrated a significant decrease in severity of skin fibrosis, a positive effect on the respiratory function and a favorable safety profile, which allows to consider it as a promising therapeutic option for SS.


  • Open Access

    Efficacy of divozilimab in the treatment of systemic sclerosis: results of the randomized phase III clinical trial BCD-132-5/LIBERIUS

    by L. P. Ananyeva, M. N. Starovoytova, I. Z. Gaydukova, G. V. Lukina, E. V. Zonova, L. V. Eliseeva, G. F. Fatkhullina, D. I. Abdulganieva, D. G. Krechikova, T. V. Kropotina, et al.

    The search for new therapeutic options for the treatment of systemic sclerosis (SSc) is an urgent issue in rheumatology. The article presents the results of the double-blind, randomized, placebo-controlled phase III clinical trial BCD-132-5/LIBERIUS on the efficacy and safety of divozilimab (BCD-132) in the treatment of SSc.Objective: to investigate the efficacy and safety of divozilimab in patients with SSc compared to placebo.Material and methods. After enrolment in the study, patients received divozilimab or placebo for 48 weeks, after which they were switched to an open-label divozilimab therapy until week 96.Results and discussion. Divozilimab was superior to placebo regarding the primary endpoint change in mRSS at week 48 compared to baseline, and the therapy had a positive effect on respiratory function parameters. Divozilimab treatment was well tolerated.Conclusion. Thus, divosilimab may represent a new therapeutic option for patients with SSc.

  • Open Access

    Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study

    by T. V. Korotaeva, V. I. Mazurov, A. M. Lila, I. Z. Gaidukova, A. L. Bakulev, A. V. Samtsov, V. R. Khairutdinov, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva

    This article presents the results of the 3-year use of netakimab (NTK), a monoclonal antibody against interleukin 17, in patients with psoriatic arthritis (PsA) as part of the phase III PATERA study. Objective: to evaluate the long-term efficacy and safety of NTK in patients with PsA over a period of 3 years. Material and methods. PATERA is a double-blind, multicenter, randomized, phase III clinical trial. 194 patients with active PsA were randomized 1:1 to NTX or placebo/NTX. NTX/placebo was administered at weeks 0, 1, 2, 4, 6, 8, 10 and 14. Placebo patients who did not achieve a 20% improvement according to ACR criteria (ACR20) at week 16 received NTX at weeks 18 and 22. Patients who achieved ACR20 received placebo at weeks 18 and 22. Subsequently, all patients received NTX. At week 54, patients who did not meet ACR20 criteria were withdrawn from the study and the remaining patients were treated in the extension phase. The total duration of NTX use in all groups was 3 years. Results and discussion. Therapeutic response achieved in the first year of treatment was maintained in the extended phase of the study. Against the background of NTX use, a significant long-term decrease in clinical manifestations of PsA was observed. Adverse events occurred mainly in the form of laboratory abnormalities and infectious diseases, which were mostly mild to moderate. Antibodies against NTK were detected in 9.3% of patients and in most cases they were formed at the end of the first and beginning of the second year of therapy. Conclusion. NTK showed a favorable safety profile with long-term use over 3 years. The clinical effect on all manifestations of PsA was maintained in most patients over a long period of time without significant loss of response.


  • Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

    by A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, et al.

    OBJECTIVE To evaluate the efficacy and safety of the anti-CD20 monoclonal antibody divozilimab (DIV) used as an intravenous infusion at a dose of 500 mg every 24 weeks during 100 weeks for the treatment of patients with multiple sclerosis (MS), including relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. MATERIAL AND METHODS The multicenter, randomized, double-blind and double-masked phase III clinical trial (CT) BCD-132-4/MIRANTIBUS (NCT05385744) included 338 adult patients with MS distributed in a 1:1 ratio into two groups: DIV 500 mg and teriflunomide (TRF) 14 mg. After screening, subjects were included in the main CT period, which consisted of two cycles of therapy over 48 weeks, then entered an additional period from weeks 49 to 100, which included three cycles of therapy. The efficacy was assessed based on the results of brain MRI and registration of data on relapses. RESULTS 308 subjects completed 5 therapy cycles according to the study protocol. An analysis of the effectiveness of DIV therapy over 2 years showed a persistent suppression of MRI and clinical activity of the disease in comparison with TRF, which was confirmed by all the studied MRI indicators (including CUA; total number of gadolinium-enhancing (GdE) lesions on T1-weighted scans ; number of new or enlarged lesions on T2-weighted scans; lesions volume change on T2-weighted scans; change in the volume of hypointense lesions on T1-weighted scans). The use of DIV was associated with a statistically significant decrease in ARR compared to TRF (p=0.0001). The ARR in the DIV group was 0.057, in the TRF group — 0.164 with 95% confidential interval for the frequency ratio [0.202; 0.593]. The incidence of GdE lesions on T1-weighted scans in the DIV group was significantly lower than in the TRF group. The average number of such lesions was 0.0±0.08 and 1.0±4.46 in the DIV and TRF groups, respectively (pp=0.0075). The proportion of patients with relapses was 11.2% (n=19) in the DIV group and 23.1% (n=39) in the TRF group (p=0.0039). In the subpopulation of patients with SPMS, no cases of increase in EDSS were detected, and not a single case of exacerbation was recorded over 2 years of using DIV. Also, DIV has shown a favorable safety profile. Among the adverse reactions (AR), infusion reactions and laboratory abnormalities, such as a decrease in the number of leukocytes, neutrophils, and lymphocytes, were most often recorded. Identified AR were expected, had mild to moderate severity, and resolved without any negative consequences. CONCLUSION The results of the BCD-132-4/MIRANTIBUS CT indicate a high sustained efficacy and safety of long-term use of DIV in comparison with TRF during 2 years of therapy.


  • Open Access

    Long-term efficacy and safety of netakimab in patients with active ankylosing spondylitis: results of three years of use in the international multicentre, randomized, double-blind, phase III clinical trial BCD-085-5/ASTERA

    by V. I. Mazurov, Sh. F. Erdes, I. Z. Gaydukova, T. V. Dubinina, A. M. Pristrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, E. S. Zhugrova, et al.

    The article presents the results of the three-year use of netakimab (NTK) in patients with ankylosing spondylitis (AS) as part of the phase III BCD-085-5/ASTERA study.Objective: to evaluate the long-term efficacy and safety of NTK over a three-year period in patients with active AS.Material and methods. BCD-085-5/ASTERA – double-blind, multicenter, randomized phase III clinical trial that enrolled patients with active AS (BASDAI ≥4) and a back pain intensity ≥4 on a numeric rating scale with inefficacy or intolerance of non-steroidal anti-inflammatory drugs or biologic drugs. A total of 228 patients were randomized in a 1:1 ratio and assigned to either the NTK group or the placebo/NTK group. Starting at week 16, patients who did not achieve ASAS20 (20% improvement according to ASAS criteria) received NTK 120 mg once every 2 weeks in an open-label regimen. Patients who achieved ASAS20 response at week 52 in the NTK group and week 68 in the placebo/NTK group continued to receive NTK (120 mg every 2 weeks) until week 156 in the NTK group and until week 172 in the placebo/NTK group.Results and discussion. Over the course of three years of NTK use, most patients experienced a sustained decline in AS activity (according to ASDAS-CRP, BASDAI) with sustained response (ASAS20/40, ASAS5/6) to therapy. Most adverse events reported were mild to moderate. 36.7% of patients had adverse events, which were mainly laboratory abnormalities, blood and lymphatic system abnormalities and infectious complications.Conclusion. The clinical effect of NTK was maintained in most patients with AS over a three-year period, with no significant loss of response. NTK was well tolerated and the safety profile remained favorable.


  • Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

    by A.N. Boyko, V.M. Alifirova, I.G. Lukashevich, Z.A. Goncharova, I.V. Greshnova, L.G. Zaslavsky, S.V. Kotov, N.A. Malkova, G.N. Mishin, E.V. Parshina, et al.

    ЦЕЛЬ ИССЛЕДОВАНИЯ Сравнение эффективности и безопасности курса дивозилимаба (ДИВ) по сравнению с терифлуномидом (ТРФ) при рассеянном склерозе (РС) с обострениями (РСО), включавшим ремиттирующий РС и вторично-прогрессирующий РС с обострениями. МАТЕРИАЛ И МЕТОДЫ Проведено многоцентровое рандомизированное двойное слепое и двойное маскированное клиническое исследование (КИ) 3 фазы BCD-132-4/MIRANTIBUS, включавшее 338 взрослых пациентов с РСО, распределенных в соотношении 1:1 в две группы: ДИВ и ТРФ. После скринингового обследования пациенты включались в основной период КИ, состоявший из двух циклов терапии в течение 48 нед. Первичной конечной точкой КИ являлась среднегодовая частота обострений через 48 нед после рандомизации последнего пациента в исследование. РЕЗУЛЬТАТЫ В соответствии с протоколом исследования 321 пациент завершил 48 нед терапию. Проведенный анализ данных эффективности по первичной конечной точке позволил доказать гипотезу превосходства исследуемого препарата ДИВ относительно ТРФ. Быстрое подавление острой активности по результатам МРТ головного мозга и клинических проявлений заболевания зарегистрировано уже после первой инфузии ДИВ у пациентов с РСО. Так, через 48 нед терапии у пациентов группы ДИВ отсутствовали очаги, накапливающие контраст в T1-режиме, при этом в группе ТРФ такие очаги отмечались у 20,7% (35/169) субъектов. Оценка показателя CUA per scan продемонстрировала, что средние значения за оцениваемый период были статистически значимо ниже в группе ДИВ по сравнению с группой ТРФ: отношение скорректированных частот per scan (ДИВ/ТРФ) составило 0,125 [95% ДИ 0,089; 0,177]. За 48 нед терапии доля пациентов с обострениями составила 9,5% (16/169) в группе ДИВ и 19,5% (33/169) — в группе ТРФ (p=0,0086). Из нежелательных реакций (НР) наиболее часто регистрировались инфузионные реакции и отклонения лабораторных данных, таких как снижение числа лейкоцитов, нейтрофилов, лимфоцитов. Выявленные НР были ожидаемыми, имели легкую и умеренную степень тяжести и разрешились без негативных последствий. ЗАКЛЮЧЕНИЕ Результаты клинического исследования указывают на высокую эффективность и безопасность ДИВ в сравнении с ТРФ.